Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

NCT05859074 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05859074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
May 4, 2023
Completion date
May 4, 2028
Enrollment
56 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adnexal carcinoma, advanced cancer, angiosarcoma, basal cell carcinoma, bcc, bcc - basal cell carcinoma, cutaneous neoplasm, cutaneous squamous cell carcinoma, extramammary paget disease, head and neck squamous cell carcinoma, hnscc, kaposi sarcoma, melanoma, merkel cell carcinoma, metastatic cancer, refractory cancer, scc - squamous cell carcinoma, sebaceous carcinoma, solid tumor